Board of Directors

Magnus Persson (Chairman) is a medical doctor and PhD from the Karolinska Institute in Sweden and co-founder of the now publicly traded Aerocrine. He has been working as a clinical doctor and early in his career he was in charge of several clinical trial programs for Sanofi that resulted in blockbuster drugs. Magnus has a long history in the pharmaceutical industry and has built up investment funds both in Sweden and abroad with a focus on medical projects – particularly as Partner at HealthCap in Sweden from inception and later as Managing Partner in San Francisco based The Column Group. In these capacities Magnus helped found and develop many successful biotech companies.

Annette Colin is currently the CFO at Biotage (BIOT (STO))and has more than 30 years’ experience from different functions within finance and management in executive positions as CEO, CFO, COO, Group Financial Controller and Tax Manager, including 14 years in Life Science. Annette Colin has been part of fast-growing companies and organizations and has long experience in building strategic plans, leadership development and streamlining infrastructure. She worked with both Venture Capital and Private Equity owners, but the majority in listed companies. Most recent assignments include Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. She has also experience as an investor and from board assignments. Annette has education in Business Administration, marketing, organizational-learn and law at Lund University, Sweden.

Henrik Moltke has more than 25 years of experience as CFO and Senior Vice President within Life sciences and Health care. The primary focus in his career has been in Venture financing, IPO as well as follow on capital increases in the public market, Investor Relations and communication, finance and project management, Strategic development and business development with companies like Scandinavian Micro Biodevices ApS, Astion Pharma A/S, NeuroSearch A/S, Novo A/S, and  Ferrosan  A/S. Henrik has also a broad experience from several listed and unlisted companies as member of the Board. Today Henrik is Chairman of the board for “Werner Richter og Hustrus Legat” a charity foundation and is board member of Hartmanns A/S. Henrik holds a master degree in International economics and strategic management from Copenhagen Business School, Denmark.

Peter Holm has a PhD in biochemistry from the Karolinska in Stockholm, and a Master's degree in chemistry from the University of Linköping. Holm is a partner and European Patent Attorney at the Patent & Trademark Office Høiberg. Holm has extensive experience in strategic global IPR and commercialization advisory services to companies and organizations in the life science sector.

Claus Elsborg Olesen earned his PhD in Physiology and Biophysics from Aarhus University in 2008 and has been engaged in both basic and applied research with an emphasis on structural biology and function of membrane proteins ever since. Furthermore, Dr. Olesen has been in involved in numerous drug development projects in both academic and industrial collaborations with both soluble and membrane protein targets. He is the author of a number of articles including two first authorship articles in Science and Nature. He is the co-founder of Pcovery ApS (2009) an antifungal Biotech situated in Copenhagen and NMD Pharma (2015) a biotech company focused on the development of new treatments for neuromuscular disorders. He is the coordinator of the Business Research Manager program at the faculty of Health at Aarhus University aimed at establishing more collaboration between the research at the university and pharmaceutical industry. He is former professional sailor having competed in the Americas Cup for Sweden in 2003 and participating in two Olympics representing Denmark.